arrow
Κ

Κonstantinos Samitas

national & kapodistrian university of athens
H指数:23
被引数:2,204

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives

关于肺癌筛查的构建性叙事综述:来自多学科工作组及患者代表的当前证据、临床实践意义和实施见解

2025-10-010
PRE
Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer

外周血免疫图谱用于预测转移性非小细胞肺癌对anti-PD-1免疫治疗的应答

2025-06-020
OA
Newly diagnosed eosinophilic granulomatosis with polyangiitis in patients on biologics for severe asthma: A multicenter case series

新诊断的嗜酸性肉芽肿性多血管炎在生物制剂治疗重症哮喘患者中的多中心病例系列

2025-04-150
PRE
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study

重度嗜酸性哮喘患者接受美泊利单抗治疗后的临床缓解:RELight研究的事后分析

2025-01-011
PRE
Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study
2024-10-300
PRE
The REALISM Study: The Experience of Pulmonologists with Benralizumab in Greece
2024-10-300
PRE
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study
2024-10-300
PRE
Oral corticosteroids and biologics use in the Greek Severe Asthma Registry (GSAR)
2024-10-300
PRE
Characteristics of never-, switching, and persisting users of biologics for severe asthma - SHARP-CRC study
2024-10-300
PRE
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study
2023-12-120
PRE
The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.
2023-10-270
PRE
Follow-up of patients with severe eosinophilic asthma receiving benralizumab for one year (gReek rEAl Life regIStry of benralizuMab: REALISM Study)
2023-10-270
PRE
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

精确肿瘤学时代EGFR外显子20突变NSCLC患者的分子流行病学和治疗模式: 欧洲异国注册中心

2023-01-0114
OA
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Patras免疫治疗评分模型对nivolumab或pembrolizumab治疗晚期NSCLC患者的预测和预后的验证: 来自欧洲多中心研究的结果

2022-09-081
OAAI